Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 400 - 601 WEST BROADWAY VANCOUVER BC V5Z 4C2 |
Tel: | N/A |
Website: | https://algernonpharmaceuticals.com |
IR: | See website |
Key People | ||
N/A |
Business Overview |
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company's lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis. |
Financial Overview |
For the three months ended 30 November 2023, Algernon Pharmaceuticals Inc revenues was not reported. Net loss decreased 72% to C$522K. Lower net loss reflects Share-based payments decrease of 88% to C$69K (expense), Marketing decrease of 82% to C$105K (expense), Research and development - Balancing va decrease of 53% to C$161K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -C$0.20 to -C$0.03. |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $2.47M as of Nov 30, 2023 |
Annual revenue (TTM): | $0.00M as of Nov 30, 2023 |
EBITDA (TTM): | -$3.84M as of Nov 30, 2023 |
Net annual income (TTM): | -$5.42M as of Nov 30, 2023 |
Free cash flow (TTM): | -$1.84M as of Nov 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 21,640,762 as of Feb 8, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |